New imaging dye could reveal hidden oxygen levels in cervix tumors

NCT ID NCT01549730

Ongoing Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a special PET scan dye called 18F-FAZA can measure low oxygen levels (hypoxia) in cervix cancer tumors. About 30 adults with cervix cancer will receive the dye before starting standard treatment with radiation and chemotherapy. The goal is to see if this imaging method is feasible and could replace older, more complex techniques for detecting hypoxia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Fluoroazomycin Arabinoside (18F-FAZA) PET scan dye
What this could lead to: If successful, this imaging method could help doctors better understand how low oxygen levels affect cervix cancer growth and treatment response.
What could go wrong: This is a small feasibility study with only 30 participants, and the dye is not yet approved for general use. The results may not change current treatment or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVIX CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVIX CANCER

Contacts and locations

Locations

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.